MX2016016173A - Forma de dosis oral solida de compuestos lipofilicos. - Google Patents
Forma de dosis oral solida de compuestos lipofilicos.Info
- Publication number
- MX2016016173A MX2016016173A MX2016016173A MX2016016173A MX2016016173A MX 2016016173 A MX2016016173 A MX 2016016173A MX 2016016173 A MX2016016173 A MX 2016016173A MX 2016016173 A MX2016016173 A MX 2016016173A MX 2016016173 A MX2016016173 A MX 2016016173A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage form
- oral dosage
- solid oral
- lipophilic compounds
- glyceride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
- A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que comprende un compuesto que tiene un log P de al menos 5 y un vehículo, en donde el vehículo comprende (a) un componente graso en una cantidad suficiente para lograr la absorción linfática en un mamífero, en donde el componente graso se selecciona de un monoglicérido de ácidos grasos de cadena larga, un triglicérido de ácidos grasos de cadena larga, y un mono- y triglicérido de ácidos grasos de cadena larga.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14173067 | 2014-06-19 | ||
PCT/EP2015/063606 WO2015193380A2 (en) | 2014-06-19 | 2015-06-17 | Solid oral dosage form of lipophilic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016016173A true MX2016016173A (es) | 2017-03-28 |
Family
ID=50980946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016016173A MX2016016173A (es) | 2014-06-19 | 2015-06-17 | Forma de dosis oral solida de compuestos lipofilicos. |
Country Status (19)
Country | Link |
---|---|
US (1) | US11197828B2 (es) |
EP (1) | EP3157508B1 (es) |
JP (2) | JP6723166B2 (es) |
KR (1) | KR102397569B1 (es) |
CN (2) | CN115463106A (es) |
AU (1) | AU2015276202B2 (es) |
BR (1) | BR112016029271B1 (es) |
CA (1) | CA2948225C (es) |
DK (1) | DK3157508T3 (es) |
EA (1) | EA036836B1 (es) |
ES (1) | ES2851332T3 (es) |
HU (1) | HUE054467T2 (es) |
IL (1) | IL249238B (es) |
MX (1) | MX2016016173A (es) |
PL (1) | PL3157508T3 (es) |
PT (1) | PT3157508T (es) |
SG (1) | SG11201609352TA (es) |
WO (1) | WO2015193380A2 (es) |
ZA (1) | ZA201700301B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2429850C2 (ru) | 2005-04-15 | 2011-09-27 | Кларус Терапьютикс, Инк. | Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих |
US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
WO2016066611A1 (en) * | 2014-10-31 | 2016-05-06 | Capsugel Belgium N.V. | Pharmaceutical compositions containing cinacalcet and methods for their preparation and use |
ES2863500T3 (es) | 2015-04-10 | 2021-10-11 | Capsugel Belgium Nv | Formulaciones lipídicas de acetato de abiraterona |
AU2017277497B2 (en) * | 2016-06-07 | 2023-05-04 | Northeastern University | Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells |
ITUA20164228A1 (it) * | 2016-06-09 | 2017-12-09 | Labomar S R L | Formulazione a matrice grassa auto-emulsionante e gastro-resistente e relativo metodo di preparazione |
CN107468650A (zh) * | 2016-10-09 | 2017-12-15 | 郑州泰丰制药有限公司 | 一种厄贝沙坦自乳化软胶囊及其制备方法 |
US20190380958A1 (en) * | 2016-12-28 | 2019-12-19 | Chugai Seiyaku Kabushiki Kaisha | Self-emulsifying drug formulation for improving membrane permeability of compound |
KR101920628B1 (ko) * | 2017-04-12 | 2018-11-22 | 대원제약주식회사 | 안지오텐신 수용체 길항제를 포함하는 약제학적 조성물 |
CA3177229A1 (en) * | 2017-08-30 | 2019-03-07 | Antares Pharma, Inc. | Testosterone ester triglyceride formulations |
WO2019087696A1 (ja) * | 2017-11-01 | 2019-05-09 | 富士フイルム株式会社 | 経口医薬組成物 |
KR102093100B1 (ko) * | 2018-07-11 | 2020-03-26 | 대화제약 주식회사 | 산화 안정성이 향상된 탁산을 포함하는 경구용 약학 조성물 |
KR102327750B1 (ko) * | 2018-12-19 | 2021-11-18 | 대화제약 주식회사 | Glp-1 유사체를 포함하는 경구투여용 약제학적 조성물 |
GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
CN116785301A (zh) * | 2019-09-26 | 2023-09-22 | 湖南慧泽生物医药科技有限公司 | 含醋酸阿比特龙的药物组合物及其制备方法和应用 |
EP3854384A1 (en) | 2020-01-27 | 2021-07-28 | Adamed Pharma S.A. | Pharmaceutical formulation comprising abiraterone acetate |
CN113456588B (zh) * | 2021-07-05 | 2023-01-03 | 沈阳药科大学 | 一种醋酸阿比特龙固体自微乳及其制备方法 |
EP4197541A1 (en) | 2021-12-15 | 2023-06-21 | Hunan Huize Biopharma S&T Co., Ltd | Abiraterone acetate-containing composition and application thereof |
CN114306236B (zh) * | 2021-12-15 | 2022-10-21 | 湖南慧泽生物医药科技有限公司 | 用于负载醋酸阿比特龙的自微乳体系及组合物和应用 |
US20230277464A1 (en) * | 2022-03-04 | 2023-09-07 | Abitec Corporation | Tablet dosage forms for lipid-based drug delivery systems |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4098802A (en) | 1975-02-18 | 1978-07-04 | Akzona Incorporated | Oral pharmaceutical preparation having androgenic activity |
RU2141967C1 (ru) | 1992-05-21 | 1999-11-27 | Андорешерш Инк. | ИНГИБИТОРЫ ТЕСТОСТЕРОН 5α-РЕДУКТАЗЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ТЕСТОСТЕРОН 5α-РЕДУКТАЗЫ |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
PL179608B1 (pl) * | 1994-04-07 | 2000-10-31 | Smithkline Beecham Plc | Samoemulgujacy, doustny srodek farmaceutyczny do leczenia malari i dozylny srodek farmaceutyczny do leczenia malarii PL PL |
WO1996033697A1 (fr) * | 1995-04-24 | 1996-10-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Formulation auto-emulsionnable formant une emulsion huile dans l'eau |
US6979456B1 (en) * | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
ATE462417T1 (de) * | 1998-08-13 | 2010-04-15 | Cima Labs Inc | Microemulsionen als feste dosisformen zur oralen verabreichung |
US6977083B1 (en) | 1998-10-02 | 2005-12-20 | Jenapharm Gmbh & Co. Kg | Bioadhesive tablet containing testosterone/testosterone ester mixtures and method for producing a predetermined testosterone time-release profile with same |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
WO2000059512A1 (en) | 1999-04-01 | 2000-10-12 | Akzo Nobel N.V. | Formulation comprising testosteron undecanoate and castor oil |
GB9907715D0 (en) | 1999-04-01 | 1999-05-26 | Scherer Corp R P | Pharmaceutical compositions |
US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
MY120392A (en) * | 2000-06-08 | 2005-10-31 | Hovid Berhad | A novel drug delivery system : formulation for fat-soluble drugs |
US6596306B1 (en) * | 2000-07-07 | 2003-07-22 | David Ho Sue San Ho | Drug delivery system:formulation for fat-soluble drugs |
US6692771B2 (en) * | 2001-02-23 | 2004-02-17 | Cima Labs Inc. | Emulsions as solid dosage forms for oral administration |
AUPR573001A0 (en) | 2001-06-15 | 2001-07-12 | Glaxo Wellcome Australia Ltd | Lymphatic drug delivery system |
US20050287203A1 (en) | 2002-05-08 | 2005-12-29 | Nijs De H | Formulation comprising testosteron undecanoate and castor oil |
US20080305177A1 (en) | 2002-11-14 | 2008-12-11 | Alvin Kershman | Method of administering testosterone |
US20040127476A1 (en) | 2002-11-14 | 2004-07-01 | Alvin Kershman | Oral testosterone delivery system with improved sustained release |
US20050100608A1 (en) | 2003-02-21 | 2005-05-12 | Watson Pharmaceuticals, Inc. | Testosterone oral dosage formulations and associated methods |
US7138389B2 (en) | 2004-02-09 | 2006-11-21 | University Of Washington | Oral androgen therapy using modulators of testosterone bioavailability |
US7345093B2 (en) * | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
CN101001613B (zh) | 2004-06-28 | 2010-09-29 | 生命周期药物公司 | 作为液体制剂载体的多孔片剂 |
WO2006035417A2 (en) * | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Dihydropyrimidine microcapsule - formulations |
RU2429850C2 (ru) | 2005-04-15 | 2011-09-27 | Кларус Терапьютикс, Инк. | Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих |
US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
GB0807605D0 (en) | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
JP4629768B2 (ja) * | 2008-12-03 | 2011-02-09 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 並列化処理方法、システム、及びプログラム |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
EP2229936B1 (en) | 2009-03-09 | 2015-05-06 | PharmaSol GmbH | Nanonized testosterone formulations for improved bioavailability |
WO2010134614A1 (ja) | 2009-05-22 | 2010-11-25 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
PT2519230T (pt) * | 2009-12-31 | 2019-01-18 | Marius Pharmaceuticals Llc | Modulação de solubilidade, estabilidade, absorção, metabolismo e perfil farmacocinético de fármacos lipofílicos por esteróis |
US20130303495A1 (en) * | 2009-12-31 | 2013-11-14 | Sov Therapeutics | Emulsion formulations |
ES2525520T3 (es) | 2010-04-12 | 2014-12-26 | Clarus Therapeutics, Inc. | Formulaciones orales de éster de testosterona y métodos para tratar la deficiencia de testosterona con las mismas |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
WO2014009434A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
US20140179655A1 (en) | 2012-12-20 | 2014-06-26 | Solural Pharma ApS | Solid oral dosage form of testosterone derivative |
-
2015
- 2015-06-17 ES ES15729188T patent/ES2851332T3/es active Active
- 2015-06-17 AU AU2015276202A patent/AU2015276202B2/en active Active
- 2015-06-17 US US15/319,773 patent/US11197828B2/en active Active
- 2015-06-17 WO PCT/EP2015/063606 patent/WO2015193380A2/en active Application Filing
- 2015-06-17 BR BR112016029271-5A patent/BR112016029271B1/pt active IP Right Grant
- 2015-06-17 PT PT157291881T patent/PT3157508T/pt unknown
- 2015-06-17 MX MX2016016173A patent/MX2016016173A/es active IP Right Grant
- 2015-06-17 CA CA2948225A patent/CA2948225C/en active Active
- 2015-06-17 KR KR1020177001552A patent/KR102397569B1/ko active IP Right Grant
- 2015-06-17 DK DK15729188.1T patent/DK3157508T3/da active
- 2015-06-17 CN CN202210900455.3A patent/CN115463106A/zh active Pending
- 2015-06-17 HU HUE15729188A patent/HUE054467T2/hu unknown
- 2015-06-17 EP EP15729188.1A patent/EP3157508B1/en active Active
- 2015-06-17 PL PL15729188T patent/PL3157508T3/pl unknown
- 2015-06-17 SG SG11201609352TA patent/SG11201609352TA/en unknown
- 2015-06-17 CN CN201580032176.8A patent/CN107073127A/zh active Pending
- 2015-06-17 EA EA201790027A patent/EA036836B1/ru not_active IP Right Cessation
- 2015-06-17 JP JP2016569987A patent/JP6723166B2/ja active Active
-
2016
- 2016-11-27 IL IL249238A patent/IL249238B/en unknown
-
2017
- 2017-01-13 ZA ZA2017/00301A patent/ZA201700301B/en unknown
-
2020
- 2020-02-17 JP JP2020024021A patent/JP7071420B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
SG11201609352TA (en) | 2017-01-27 |
EA036836B1 (ru) | 2020-12-25 |
JP7071420B2 (ja) | 2022-05-18 |
WO2015193380A2 (en) | 2015-12-23 |
WO2015193380A3 (en) | 2016-02-11 |
HUE054467T2 (hu) | 2021-09-28 |
KR20170020479A (ko) | 2017-02-22 |
AU2015276202A1 (en) | 2017-02-02 |
KR102397569B1 (ko) | 2022-05-12 |
IL249238B (en) | 2022-04-01 |
BR112016029271A2 (pt) | 2017-08-22 |
AU2015276202B2 (en) | 2020-09-17 |
EP3157508A2 (en) | 2017-04-26 |
CN107073127A (zh) | 2017-08-18 |
CN115463106A (zh) | 2022-12-13 |
ZA201700301B (en) | 2022-01-26 |
BR112016029271B1 (pt) | 2023-04-04 |
ES2851332T3 (es) | 2021-09-06 |
EA201790027A1 (ru) | 2017-05-31 |
PL3157508T3 (pl) | 2021-05-17 |
JP2020090538A (ja) | 2020-06-11 |
JP2017518294A (ja) | 2017-07-06 |
EP3157508B1 (en) | 2020-12-09 |
CA2948225C (en) | 2022-05-31 |
CA2948225A1 (en) | 2015-12-23 |
NZ728110A (en) | 2023-09-29 |
US20170119674A1 (en) | 2017-05-04 |
US11197828B2 (en) | 2021-12-14 |
PT3157508T (pt) | 2021-02-17 |
DK3157508T3 (da) | 2021-02-15 |
JP6723166B2 (ja) | 2020-07-15 |
IL249238A0 (en) | 2017-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016016173A (es) | Forma de dosis oral solida de compuestos lipofilicos. | |
CL2013003019A1 (es) | Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. | |
CL2015002164A1 (es) | Formulación combinada de dos compuesos antivirales. | |
BR112016002081A2 (pt) | composições de limpeza contendo uma poliéter amina | |
ZA201900146B (en) | Lysine: hydrochloride synthetic acid compositions as alternatives to conventional acids in the oil and gas industry | |
PL3092266T3 (pl) | Kompozycja plastyfikatora zawierająca pochodną furanu i ester kwasu 1,2-cykloheksanodikarboksylowego | |
MY190647A (en) | Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof | |
HK1243924A1 (zh) | 用於治療炎症病理的脂肪酸(f.a.g.,脂肪酸族)混合物 | |
UA117032C2 (uk) | Селективний інгібітор фосфатидилінозитол-3-кінази-гамма | |
PH12015501783B1 (en) | Pharmaceutical compositions for the treatment of helicobacter pylori | |
CL2015002832A1 (es) | Formulación farmaceutica que comprende fosfatidilcolina para el tratamiento de colitus ulcerosa. | |
MX360186B (es) | Forma de dosificacion oral solida de derivado de testosterona. | |
GB201611497D0 (en) | Compositions for use in enriching animal meat with omega-3 polyunsaturated fatty acids | |
AR100028A1 (es) | Composiciones nutricionales que contienen ácido estearidónico | |
EP2964750A4 (en) | METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES | |
HK1255345A1 (zh) | 含有高濃度紫杉烷的用於口服給藥的藥物組合物 | |
CL2015001104A1 (es) | Composición de la alimentación para peces | |
PH12015502727A1 (en) | Methods and compositions for enhancing cognitive performance | |
MX2015012771A (es) | Procedimiento de tratamiento de la deficiencia de vitamina b12. | |
BR112016028561A8 (pt) | composição e forma de dosagem compreendendo um óleo marinho que compreende ácidos graxos, e, uso das mesmas | |
AR100204A1 (es) | Compuesto de 1,1-adipoilbis(pirrolidina-2-carboxilato), composición farmacéutica que lo comprende y conjunto de partes que los incluye | |
MX2015013739A (es) | Potenciadores de solubilidad del agua a base de glucogeno. | |
EA201790117A1 (ru) | Фармацевтическая композиция, содержащая 13 глицеридов, и ее препараты и их применение | |
GB201611503D0 (en) | Compositions for use in enriching animal meat with omega-3 polyunsaturated fatty acids | |
WO2015123480A3 (en) | Compositions and methods for the prevention and/or treatment of schistosomiasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |